BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Actemra regulatory update

The U.K.'s NICE issued final guidance recommending RoActemra tocilizumab from Roche to treat systemic juvenile idiopathic arthritis (sJIA) in patients ages >=2 years who have responded inadequately to NSAIDs, systemic corticosteroids or methotrexate. The recommendation is contingent on a patient access scheme...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >